Leukemia: Surprise Discovery! Cancer drug treatment COVID-19 acute respiratory distress patients!

, July 6, 2020 /
BIOON/-- Although the ongoing SARS-CoV-2 coronavirus usually causes only mild respiratory symptoms, COVID-19 develops severe to the potential for acute respiratory distress in about 5% of those infectedDr Thomas Wiesmann, who was involved in patient treatment with the intensive care team in the anaesthetic and intensive care unit at Marburg University Hospital, said: "The mortality rate in these cases is very high"
patient was a 65-year-old woman with no previous medical history and was admitted to hospital with sexual shortness of breath and feverHer shortness of breath deteriorated so fast that she had to intubate for artificial respiration three hours after being admitted to hospitalA standard moleculargenetictest confirmed that she was infected with SARS-CoV-2Due to extensive organ damage, the patient's overall prognosis assessment is very poor"We know from Chinese publications that patients with severe or even fatal diseases often experience so-called cytokine storms," said Neubauer,During cytokine storms, the body is filled with substances that stimulate the immune systemOverreaction sourfing the body's own defense system sits tissues and makes it easier for invading viruses to spreadpicture source: Suspected patients may react to a drug originally used for cancer treatment, russotinibIt inhibits enzymes in the body that are involved in excessive inflammatory reactions"We recommend to our patients that this cancer drug may be able to prevent the life-threatening effects of inflammation of lung tissue," Neubauer said "
" we face a difficult decision," added Professor Hinnerk Wulf, director of the Department of Anesthesiology and Intensive Care "It's not clear whether this theory can also work in practice; after all, experimental therapy is also associated with risk." In fact, patients at the University of Marburg School of Medicine did improve after receiving Russotinib The treatment team noted clinical stability and rapid improvements in respiratory and heart function "Compared to other patients, the procedure is significant," Wiesmann stressed The patient gradually stopped using the ventilator on the 10th day of hospitalization Virus replication is also reduced during the use of anti-cancer drugs "
clearly, the success of this treatment is not a case in point The team at the University of Marburg also used the anticancer drug in several other patients to control the severity of the condition Neubauer explains: "For all patients who have been receiving cancer drugs for more than a week, the results are good A team led by Professor Paul Graf La Rosee of Schwarzwald-Baar Hospital also reported the successful use of immunosuppressants, albeit in less severe cases "The time interval between the start of use of Russotinib and the improvement of health is so short that we have reason to think that Russotinib is part of a beneficial clinical process," Neubauer explains Based on the success of this treatment, the German Federal Institute for Medicine and Medical Devices approved a clinical trial to test the effects of russotinib in other COVID-19 patients (BioValleyBioon.com) References: Cancer Drug cures COVID-19 Patient with acute distress Andreas Neubauer et al, Ruxolitinib for treatment of SARS-CoV-2 induced breath a breath of acute distress syndrome (ARDS), Leukemia (2020) DOI: 10.1038/s41375-020-0907-9